[go: up one dir, main page]

DK0725642T3 - Stabiliseret prostaglandin E1 - Google Patents

Stabiliseret prostaglandin E1

Info

Publication number
DK0725642T3
DK0725642T3 DK94927958T DK94927958T DK0725642T3 DK 0725642 T3 DK0725642 T3 DK 0725642T3 DK 94927958 T DK94927958 T DK 94927958T DK 94927958 T DK94927958 T DK 94927958T DK 0725642 T3 DK0725642 T3 DK 0725642T3
Authority
DK
Denmark
Prior art keywords
formulation
lactose
pct
pge
tertiary butyl
Prior art date
Application number
DK94927958T
Other languages
English (en)
Inventor
Dirk L Teagarden
Paul M Gold
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of DK0725642T3 publication Critical patent/DK0725642T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK94927958T 1993-10-27 1994-09-06 Stabiliseret prostaglandin E1 DK0725642T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14369593A 1993-10-27 1993-10-27
PCT/US1994/009648 WO1995011683A1 (en) 1993-10-27 1994-09-06 Stabilized prostaglandin e¿1?

Publications (1)

Publication Number Publication Date
DK0725642T3 true DK0725642T3 (da) 2000-05-29

Family

ID=22505188

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94927958T DK0725642T3 (da) 1993-10-27 1994-09-06 Stabiliseret prostaglandin E1

Country Status (16)

Country Link
US (2) US5741523A (da)
EP (1) EP0725642B1 (da)
JP (1) JP3999263B2 (da)
KR (1) KR100335549B1 (da)
CN (1) CN1060042C (da)
AT (1) ATE187071T1 (da)
AU (1) AU688792B2 (da)
DE (1) DE69421936T2 (da)
DK (1) DK0725642T3 (da)
ES (1) ES2142409T3 (da)
FI (1) FI116270B (da)
GR (1) GR3032817T3 (da)
NO (1) NO309126B1 (da)
NZ (1) NZ273752A (da)
PT (1) PT725642E (da)
WO (1) WO1995011683A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
KR100195348B1 (ko) * 1996-10-31 1999-06-15 장용택 안정한 프로스타글란딘 e1-함유 주사제 조성물
JP2001509480A (ja) 1997-07-09 2001-07-24 アンドロソリューションズ，インク． 男性勃起機能不全を治療するための改良された方法及び組成物
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
EA003864B1 (ru) * 1998-03-03 2003-10-30 ШИОНОГИ энд КО.,ЛТД. КОМПОЗИЦИЯ И СПОСОБ ПРИГОТОВЛЕНИЯ ФАРМАЦЕВТИЧЕСКОГО СОСТАВА, ЛИОФИЛИЗИРОВАННАЯ КОМПОЗИЦИЯ И ЕЕ ПРИМЕНЕНИЕ, СПОСОБ ИНГИБИРОВАНИЯ sPLA2-ОПОСРЕДОВАННОГО ВЫСВОБОЖДЕНИЯ ЖИРНОЙ КИСЛОТЫ, СПОСОБ ЛЕЧЕНИЯ МЛЕКОПИТАЮЩИХ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ СЕПСИСА, ЗАКРЫТАЯ ЕМКОСТЬ
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6264981B1 (en) † 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
CA2543296A1 (en) * 2003-10-31 2005-05-12 Point Biomedical Corporation Reconstitutable microsphere compositions useful as ultrasonic contrast agents
JP2008519047A (ja) * 2004-11-05 2008-06-05 セフアロン・インコーポレーテツド 癌処置
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
US7582312B2 (en) 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
JPWO2006075690A1 (ja) * 2005-01-14 2008-06-12 小野薬品工業株式会社 安定な医薬組成物
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US9005183B2 (en) * 2007-05-16 2015-04-14 Health Knight, Llc System and method for treating erectile dysfunction
US20100222785A1 (en) * 2007-08-03 2010-09-02 Vanderbilt University Anchor driver
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2889029A1 (en) * 2008-09-25 2015-07-01 Cephalon, Inc. Liquid formulations of bendamustine
KR20110110293A (ko) * 2009-01-15 2011-10-06 세파론, 인코포레이티드 벤다무스틴 유리 염기의 신규 형태
PL2528602T5 (pl) 2010-01-28 2020-09-07 Eagle Pharmaceuticals, Inc. Preparaty bendamustyny
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
AT518009A1 (de) * 2015-07-27 2017-06-15 Gebro Holding Gmbh Konzentrat enthaltend Alprostadil
CN109394704B (zh) * 2018-11-27 2021-09-17 西安力邦肇新生物科技有限公司 一种前列腺素e1甲酯注射用冻干制剂及制备和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927197A (en) * 1974-04-19 1975-12-16 Pfizer Tertiary alcohol stabilized E-series prostaglandins
US3952004A (en) * 1974-06-18 1976-04-20 Pfizer Inc. Stabilized E-series prostaglandins
US4113882A (en) * 1974-10-21 1978-09-12 Yamanouchi Pharmaceutical Co., Ltd. Stabilized oral prostaglandin formulation and the process for the preparation thereof
AU617678B2 (en) * 1987-05-22 1991-12-05 Liposome Company, Inc., The Prostaglandin-lipid formulations

Also Published As

Publication number Publication date
GR3032817T3 (en) 2000-06-30
JP3999263B2 (ja) 2007-10-31
NO309126B1 (no) 2000-12-18
ATE187071T1 (de) 1999-12-15
KR100335549B1 (ko) 2002-11-29
DE69421936D1 (de) 2000-01-05
AU7716794A (en) 1995-05-22
CN1060042C (zh) 2001-01-03
CN1133561A (zh) 1996-10-16
DE69421936T2 (de) 2000-06-29
WO1995011683A1 (en) 1995-05-04
KR960705572A (ko) 1996-11-08
FI116270B (fi) 2005-10-31
FI961797L (fi) 1996-04-26
PT725642E (pt) 2000-05-31
EP0725642A1 (en) 1996-08-14
US5741523A (en) 1998-04-21
AU688792B2 (en) 1998-03-19
NO961718L (no) 1996-04-29
ES2142409T3 (es) 2000-04-16
FI961797A0 (fi) 1996-04-26
JPH09504529A (ja) 1997-05-06
NZ273752A (en) 1998-03-25
US5770230A (en) 1998-06-23
NO961718D0 (no) 1996-04-29
EP0725642B1 (en) 1999-12-01

Similar Documents

Publication Publication Date Title
ATE187071T1 (de) Stabilisiertes prostaglandin e1
BR9707270A (pt) Processo para o tratamento de tabaco
DE69503604D1 (de) Stabilisierte orthokieselsäure enthaltende zubereitung sowie biologische zubereitung
GEP20002205B (en) Copolymer-1; Composition for Treating Disseminated Sclerosis, Method for Production of Copolymer-1
SE8702907D0 (sv) Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same
KR850007378A (ko) 인터로이킨-2의 안정화 조성물의 제조방법
EE03047B1 (et) Kristalliline veevaba laktitool, selle valmistamise meetod ja kasutamine
KR870006901A (ko) 인터로이킨-2 조성물의 제조방법
KR880013572A (ko) 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도
US5849473A (en) Method of lyophilization of mammalian sperm cells
DE60207039D1 (de) Verfahren zur herstellung von kaffeearomazusammensetzungen
NO951547L (no) Fremgangsmåte for fremstilling av krystaller av veksthormon og krystaller fremstilt ved fremgangsmåten
Jennings et al. Effect of E. coli endotoxin on temperature, oxygen consumption and brown adipose tissue thermogenesis in rats and mice
FI79469C (fi) Foerfarande foer framstaellning av haollbara, rikligt verkningsaemnen innehaollande kamomillextrakt.
KR860008168A (ko) 니트로푸란 유도체의 제조방법
KR840002657A (ko) 인터페론 조성물의 제조방법
KR910016734A (ko) 광학활성 알킬렌디옥시벤젠 유도체 및 치료에의 용도
EA200200680A1 (ru) Применение регулятора роста растений на основе семикарбазона для раннего останавливания роста культурных растений
Bodnaryk Levels of brain cyclic AMP and cyclic GMP during the initiation of adult development in the bertha armyworm, Mamestra configurata Wlk
CA2294716A1 (en) Method for drying anhydrous paroxetine hydrochloride
KR900018013A (ko) 시아노아세트아미드 유도체, 그의 제조방법 및 그를 유효 성분으로서 함유하는 식물 병해 방제제
PT101007A (pt) Preparado liofilizado e estavel de icrf-187 e seu uso e processo de preparacao de liofilizado de icrf-187
BR0314187A (pt) Processo para produzir cristais do hormÈnio do crescimento
Phillips et al. Cuticle protein in adult Locusta migratoria
Reite et al. Mast cell depletion: Effect on the absorption of intraperitoneally injected basic histamine releasing agents